Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation

Diagnostic Microbiology and Infectious Disease

Volumn 62, Issue 3, 2008, Pages 292-297

  Ikawa, Kazuro ^a   Morikawa, Norifumi ^a   Ikeda, Kayo ^a   Ohge, Hiroki ^a   Sueda, Taijiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Doripenem; Intra abdominal infections; Monte Carlo simulation; Peritoneal fluid; Pharmacodynamics; Population pharmacokinetics

Indexed keywords

DORIPENEM;

ABDOMINAL INFECTION; ADULT; ARTICLE; BACTERIUM ISOLATE; CLINICAL ARTICLE; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; KLEBSIELLA; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PERITONEAL FLUID LEVEL; PRIORITY JOURNAL; PROBABILITY; PSEUDOMONAS AERUGINOSA;

ADULT; ALGORITHMS; ANTI-BACTERIAL AGENTS; ASCITIC FLUID; CARBAPENEMS; FEMALE; GRAM-NEGATIVE BACTERIA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; SURGICAL WOUND INFECTION; YOUNG ADULT;

EID: 53949107667     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.06.016     Document Type: Article

References (16)

1. Anderson D.L. Doripenem. Drugs Today 42 (2006) 399-404
2. Bhavnani S.M., Hammel J.P., Cirincione B.B., Wikler M.A., and Ambrose P.G. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob. Agents Chemother. 49 (2005) 3944-3947
3. DeRyke C.A., Kuti J.L., and Nicolau D.P. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn. Microbiol. Infect. Dis. 58 (2007) 337-344
4. Goldstein E.J., and Snydman D.R. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J. Antimicrob. Chemother. 53 Suppl 2 (2004) ii29-ii36
5. Ikawa K., Morikawa N., Hayato S., Ikeda K., Ohge H., and Sueda T. Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients. Int. J. Antimicrob. Agents 30 (2007) 270-273
6. Ikawa K., Morikawa N., Urakawa N., Ikeda K., Ohge H., and Sueda T. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients. J. Antimicrob. Chemother. 60 (2007) 1395-1397
7. Ikeda K., Ikawa K., Morikawa N., Kameda K., Urakawa N., Ohge H., and Sueda T. Quantification of doripenem in human plasma and peritoneal fluid by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 867 (2008) 20-25
8. Jones R.N., Huynh H.K., Biedenbach D.J., Fritsche T.R., and Sader H.S. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J. Antimicrob. Chemother. 54 (2004) 144-154
9. Nakashima M., and Oguma T. Phase I study of doripenem, a new carbapenem antibiotic for injection in healthy volunteers. Jpn. J. Chemother. 53 Suppl 1 (2005) 104-123
10. Rossi F., Baquero F., Hsueh P.R., Paterson D.L., Bochicchio G.V., Snyder T.A., Satishchandran V., McCarroll K., DiNubile M.J., and Chow J.W. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J. Antimicrob. Chemother. 58 (2006) 205-210
11. Sheiner B.L., and Beal S.L. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J. Pharmacokinet. Biopharm. 9 (1981) 635-651
12. Tam V.H., McKinnon P.S., Akins R.L., Rybak M.J., and Drusano G.L. Pharmacodynamics of cefepime in patients with Gram-negative infections. J. Antimicrob. Chemother. 50 (2002) 425-428
13. Uehara S., Murao W., Seno Y., Andoh E., Monden K., Kariyama R., Tsugawa M., Nakashima M., and Kumon H. Pharmacokinetics of doripenem in patients with renal dysfunction. Jpn. J. Chemother. 53 Suppl. 1 (2005) 130-135
14. Yafune A., Naito H., and Takebe M. Population pharmacokinetic approach with Monte Carlo integration for clinical phase I trial of pilocarpine HCl tablet. Jpn. J. Clin. Pharmacol. Ther. 30 (1999) 423-433
15. Yoshida I., Fujimura T., Jinushi Y., Higashiyama I., Sugimori G., and Yamano Y. Antimicrobial susceptibility of clinical isolates of aerobic Gram-negative bacteria in 2002. Jpn. J. Chemother. 54 (2006) 355-377
16. Zhanel G.G., Wiebe R., Dilay L., Thomson K., Rubinstein E., Hoban D.J., Noreddin A.M., and Karlowsky J.A. Comparative review of the carbapenems. Drugs 67 (2007) 1027-1052